Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor: Difference between revisions
(New page: {{SI}} {{WikiDoc Cardiology Network Infobox}} {{CMG}} '''Associate Editor-in-Chief:''' Smita Kohli, M.D.; Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S. {{Editor Join}} ...) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{ | {{Unstable angina / NSTEMI}} | ||
{{CMG}} | {{CMG}}; '''Associate Editors-in-Chief:''' [[Varun Kumar]], M.B.B.S.; [[Lakshmi Gopalakrishnan]], M.B.B.S.; Smita Kohli, M.D. | ||
'''Associate | |||
==Glycoprotein IIb/IIIa Inhibitors in the Management of Unstable angina /NSTEMI== | ==Glycoprotein IIb/IIIa Inhibitors in the Management of Unstable angina /NSTEMI== | ||
| Line 12: | Line 8: | ||
'''Mechanism of action:''' | '''Mechanism of action:''' | ||
*GP IIb/IIIa inhibitors inhibit the [[fibrinogen]]-mediated cross linkage of platelets, which is the final common pathway of platelet aggregation. | *GP IIb/IIIa inhibitors inhibit the [[fibrinogen]]-mediated cross linkage of platelets, which is the final common pathway of platelet aggregation. | ||
'''Clinical trial data:''' | '''Clinical trial data:''' | ||
| Line 18: | Line 13: | ||
*Most recently, EARLY ACS trial<ref name="pmid19332455">{{cite journal |author=Giugliano RP, White JA, Bode C, ''et al.'' |title=Early versus delayed, provisional eptifibatide in acute coronary syndromes |journal=N. Engl. J. Med. |volume=360 |issue=21 |pages=2176–90 |year=2009 |month=May |pmid=19332455 |doi=10.1056/NEJMoa0901316 |url=}}</ref> revealed that in patients who had acute coronary syndromes without ST-segment elevation, the use of [[eptifibatide]] 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. Potential benefit with this class of drugs also led to study of oral GP IIa/IIIb inhibitors. | *Most recently, EARLY ACS trial<ref name="pmid19332455">{{cite journal |author=Giugliano RP, White JA, Bode C, ''et al.'' |title=Early versus delayed, provisional eptifibatide in acute coronary syndromes |journal=N. Engl. J. Med. |volume=360 |issue=21 |pages=2176–90 |year=2009 |month=May |pmid=19332455 |doi=10.1056/NEJMoa0901316 |url=}}</ref> revealed that in patients who had acute coronary syndromes without ST-segment elevation, the use of [[eptifibatide]] 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. Potential benefit with this class of drugs also led to study of oral GP IIa/IIIb inhibitors. | ||
*A major study involving [[Orbofiban]](an oral GP IIb/IIIa inhibitor) failed to demonstrate improved outcomes and was associated with increased mortality<ref name="pmid10889124">{{cite journal |author=Cannon CP, McCabe CH, Wilcox RG, ''et al.'' |title=Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial |journal=Circulation |volume=102 |issue=2 |pages=149–56 |year=2000 |month=July |pmid=10889124 |doi= |url=}}</ref>. | *A major study involving [[Orbofiban]](an oral GP IIb/IIIa inhibitor) failed to demonstrate improved outcomes and was associated with increased mortality<ref name="pmid10889124">{{cite journal |author=Cannon CP, McCabe CH, Wilcox RG, ''et al.'' |title=Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial |journal=Circulation |volume=102 |issue=2 |pages=149–56 |year=2000 |month=July |pmid=10889124 |doi= |url=}}</ref>. | ||
'''Indications:''' | '''Indications:''' | ||
| Line 41: | Line 35: | ||
===Class I=== | ===Class I=== | ||
'''1.''' Patients with definite [[Unstable angina]] / [[NSTEMI]] at medium or high risk and in whom an initial invasive strategy is selected should receive dual-antiplatelet therapy on presentation. (Level of Evidence: A) [[ASA]] should be initiated on presentation. (Level of Evidence: A) The choice of a second antiplatelet therapy to be added to ASA on presentation includes 1 of the following: | '''1.''' Patients with definite [[Unstable angina]] / [[NSTEMI]] at medium or high risk and in whom an initial invasive strategy is selected should receive dual-antiplatelet therapy on presentation. ''(Level of Evidence: A)'' [[ASA]] should be initiated on presentation. ''(Level of Evidence: A)''The choice of a second antiplatelet therapy to be added to ASA on presentation includes 1 of the following: | ||
'''Before PCI:''' | '''Before PCI:''' | ||
*[[Clopidogrel]] (Level of Evidence: B); or | *[[Clopidogrel]] ''(Level of Evidence: B)''; or | ||
*An IV GP IIb/IIIa inhibitor. (Level of Evidence: A) IV [[eptifibatide]] or [[tirofiban]] are the preferred [[GP IIb/IIIa inhibitors]]. | *An IV GP IIb/IIIa inhibitor. ''(Level of Evidence: A)'' IV [[eptifibatide]] or [[tirofiban]] are the preferred [[GP IIb/IIIa inhibitors]]. | ||
'''At the time of PCI:''' | '''At the time of PCI:''' | ||
*[[Clopidogrel]] if not started before [[PCI]] (Level of Evidence: A); or | *[[Clopidogrel]] if not started before [[PCI]] ''(Level of Evidence: A)''; or | ||
*[[Prasugrel]] (Level of Evidence: B); or | *[[Prasugrel]] ''(Level of Evidence: B)''; or | ||
*An IV [[GP IIb/IIIa inhibitor]]. (Level of Evidence: A) | *An IV [[GP IIb/IIIa inhibitor]]. ''(Level of Evidence: A)'' | ||
'''2.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial invasive strategy is selected, [[antiplatelet therapy]] in addition to [[aspirin]] should be initiated before diagnostic angiography (upstream) with either [[clopidogrel]] (loading dose followed by daily maintenance dose) or an intravenous [[GP IIb/IIIa inhibitor]]. ''(Level of Evidence: A)'' [[Abciximab]] as the choice for upstream GP IIb/IIIa therapy is indicated only if there is no appreciable delay to angiography and PCI is likely to be performed; otherwise, IV [[eptifibatide]] or [[tirofiban]] is the preferred choice of GP IIb/IIIa inhibitor. ''(Level of Evidence: B)'' | |||
'''3.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, if recurrent symptoms/[[ischemia]], [[HF]], or serious [[arrhythmia]]s subsequently appear, then diagnostic angiography should be performed. (Level of Evidence: A). Either an IV GP IIb/IIIa inhibitor ([[eptifibatide]] or [[tirofiban]] ''[Level of Evidence: A]'') or [[clopidogrel]] (loading dose followed by daily maintenance dose ''[Level of Evidence: B]'') should be added to [[ASA]] and anticoagulant therapy before diagnostic [[angiography]] (upstream). ''(Level of Evidence: C)'' | |||
'''3.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, if recurrent symptoms/[[ischemia]], [[HF]], or serious [[arrhythmia]]s subsequently appear, then diagnostic angiography should be performed. (Level of Evidence: A). Either an IV GP IIb/IIIa inhibitor ([[eptifibatide]] or [[tirofiban]] [Level of Evidence: A]) or [[clopidogrel]] (loading dose followed by daily maintenance dose [Level of Evidence: B]) should be added to [[ASA]] and anticoagulant therapy before diagnostic [[angiography]] (upstream). (Level of Evidence: C) | |||
===Class IIa=== | ===Class IIa=== | ||
'''1.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected and who have recurrent ischemic discomfort with [[clopidogrel]], [[ASA]], and [[anticoagulant therapy]], it is reasonable to add a [[GP IIb/IIIa antagonist]] before [[diagnostic angiography]]. (Level of Evidence: C) | '''1.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected and who have recurrent ischemic discomfort with [[clopidogrel]], [[ASA]], and [[anticoagulant therapy]], it is reasonable to add a [[GP IIb/IIIa antagonist]] before [[diagnostic angiography]]. ''(Level of Evidence: C)'' | ||
'''2.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial invasive strategy is selected, it is reasonable to omit administration of an IV [[GP IIb/IIIa inhibitor]] if [[bivalirudin]] is selected as the anticoagulant and at least 300 mg of [[clopidogrel]] was administered at least 6 hours earlier than planned catheterization or [[PCI]]. ''(Level of Evidence: B)'' | |||
'''2.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial invasive strategy is selected, it is reasonable to omit administration of an IV [[GP IIb/IIIa inhibitor]] if [[bivalirudin]] is selected as the anticoagulant and at least 300 mg of [[clopidogrel]] was administered at least 6 hours earlier than planned catheterization or [[PCI]]. (Level of Evidence: B) | |||
===Class IIb=== | ===Class IIb=== | ||
'''1.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative (i.e., noninvasive) strategy is selected, it may be reasonable to add [[eptifibatide]] or [[tirofiban]] to anticoagulant and oral antiplatelet therapy. (Level of Evidence: B) | '''1.''' For [[Unstable angina]] / [[NSTEMI]] patients in whom an initial conservative (i.e., noninvasive) strategy is selected, it may be reasonable to add [[eptifibatide]] or [[tirofiban]] to anticoagulant and oral antiplatelet therapy. ''(Level of Evidence: B)'' | ||
'''2.''' The use of upstream [[GP IIb/IIIa inhibitors]] may be considered in high-risk [[Unstable angina]] / [[NSTEMI]] patients already receiving [[ASA]] and a [[thienopyridine]] who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, [[diabetes]], or significant [[ST-segment depression]], and who are not otherwise at high risk for bleeding. ''(Level of Evidence: B)'' | |||
'''2.''' The use of upstream [[GP IIb/IIIa inhibitors]] may be considered in high-risk [[Unstable angina]] / [[NSTEMI]] patients already receiving [[ASA]] and a [[thienopyridine]] who are selected for an invasive strategy, such as those with elevated [[troponin]] levels, [[diabetes]], or significant [[ST-segment depression]], and who are not otherwise at high risk for bleeding. (Level of Evidence: B) | |||
===Class III=== | ===Class III=== | ||
'''No Benefit''' | '''No Benefit''' | ||
'''1.''' [[Abciximab]] should not be administered to patients in whom [[PCI]] is not planned. (Level of Evidence: A) | '''1.''' [[Abciximab]] should not be administered to patients in whom [[PCI]] is not planned. ''(Level of Evidence: A)'' | ||
'''2.''' In [[Unstable angina]] / [[NSTEMI]] patients who are at low risk for [[ischemic]] events (e.g., [[TIMI risk score ≥2]]) or at high risk of bleeding and who are already receiving [[ASA]] and [[clopidogrel]], upstream [[GP IIb/IIIa inhibitors]] are not recommended. ''(Level of Evidence: B)''}} | |||
==See Also== | ==See Also== | ||
| Line 88: | Line 77: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
[[Category:Cardiology]] | |||
[[Category:Emergency medicine]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 23:58, 9 July 2011
|
Unstable angina / NSTEMI Microchapters |
|
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders |
|
Special Groups |
|
Diagnosis |
|
Laboratory Findings |
|
Treatment |
|
Antitplatelet Therapy |
|
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy |
|
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS |
|
Mechanical Reperfusion |
|
Discharge Care |
|
Case Studies |
|
Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor On the Web |
|
FDA on Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor |
|
CDC onUnstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor |
|
Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor in the news |
|
Blogs on Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor |
|
to Hospitals Treating Unstable angina non ST elevation myocardial infarction GPIIb/IIIa inhibitor |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Smita Kohli, M.D.
Glycoprotein IIb/IIIa Inhibitors in the Management of Unstable angina /NSTEMI
Three agents currently available are Abciximab, Eptifibatide and Tirofiban, all three of which are now included by the ACC/AHA guidelines for use in PCI.
Mechanism of action:
- GP IIb/IIIa inhibitors inhibit the fibrinogen-mediated cross linkage of platelets, which is the final common pathway of platelet aggregation.
Clinical trial data:
- ISAR-REACT 2 trial[1] studied Abciximab in NSTEMI patients. This was a multicenter, randomized, double-blind, placebo-controlled study enrolling 2022 patients with non-ST-segment elevation ACS undergoing PCI. Results showed that Abciximab reduces the risk of adverse events in patients with non-ST-segment elevation ACS undergoing PCI after pretreatment with 600 mg of clopidogrel.
- Most recently, EARLY ACS trial[2] revealed that in patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion. Potential benefit with this class of drugs also led to study of oral GP IIa/IIIb inhibitors.
- A major study involving Orbofiban(an oral GP IIb/IIIa inhibitor) failed to demonstrate improved outcomes and was associated with increased mortality[3].
Indications:
- The benefits provided by abciximab appear to be confined to patients presenting with an elevated troponin level.
- The benefit of GP IIb/IIIa inhibition appears greater when used in high-risk patients and in those with ST segment changes.
- The benefit was also seen in high risk patients with or without revascularization.
Contraindications:
- Abciximab is not recommended if PCI is not planned. Eptifibatide and Tirofiban are preferred agents when delay in coronary angiography and PCI is anticipated.
Dosing:
- All three agents are for intravenous usage and are given by bolus and continuous infusion.
- Optimal timing of GP IIb/IIIa inhibition remains controversial with no clear data available from current trials. More so, most of the trials related to timing of GP IIa/IIIb inhibitors involve patients with STEMI and hence cannot be applied to all ACS patients.
Disadvantage of GP IIb/IIIa inhibitors:
- A major side effect of GP IIb/IIIa inhibitors is thrombocytopenia and hence increased bleeding. Therefore, platelet monitoring is indicated during its use.
ACC / AHA Guidelines for Antiplatelet therapy in Unstable Angina/NSTEMI (DO NOT EDIT) [4]
| “ |
Class I1. Patients with definite Unstable angina / NSTEMI at medium or high risk and in whom an initial invasive strategy is selected should receive dual-antiplatelet therapy on presentation. (Level of Evidence: A) ASA should be initiated on presentation. (Level of Evidence: A)The choice of a second antiplatelet therapy to be added to ASA on presentation includes 1 of the following: Before PCI:
At the time of PCI:
2. For Unstable angina / NSTEMI patients in whom an initial invasive strategy is selected, antiplatelet therapy in addition to aspirin should be initiated before diagnostic angiography (upstream) with either clopidogrel (loading dose followed by daily maintenance dose) or an intravenous GP IIb/IIIa inhibitor. (Level of Evidence: A) Abciximab as the choice for upstream GP IIb/IIIa therapy is indicated only if there is no appreciable delay to angiography and PCI is likely to be performed; otherwise, IV eptifibatide or tirofiban is the preferred choice of GP IIb/IIIa inhibitor. (Level of Evidence: B) 3. For Unstable angina / NSTEMI patients in whom an initial conservative strategy is selected, if recurrent symptoms/ischemia, HF, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed. (Level of Evidence: A). Either an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban [Level of Evidence: A]) or clopidogrel (loading dose followed by daily maintenance dose [Level of Evidence: B]) should be added to ASA and anticoagulant therapy before diagnostic angiography (upstream). (Level of Evidence: C) Class IIa1. For Unstable angina / NSTEMI patients in whom an initial conservative strategy is selected and who have recurrent ischemic discomfort with clopidogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP IIb/IIIa antagonist before diagnostic angiography. (Level of Evidence: C) 2. For Unstable angina / NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to omit administration of an IV GP IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 hours earlier than planned catheterization or PCI. (Level of Evidence: B) Class IIb1. For Unstable angina / NSTEMI patients in whom an initial conservative (i.e., noninvasive) strategy is selected, it may be reasonable to add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy. (Level of Evidence: B) 2. The use of upstream GP IIb/IIIa inhibitors may be considered in high-risk Unstable angina / NSTEMI patients already receiving ASA and a thienopyridine who are selected for an invasive strategy, such as those with elevated troponin levels, diabetes, or significant ST-segment depression, and who are not otherwise at high risk for bleeding. (Level of Evidence: B) Class IIINo Benefit 1. Abciximab should not be administered to patients in whom PCI is not planned. (Level of Evidence: A) 2. In Unstable angina / NSTEMI patients who are at low risk for ischemic events (e.g., TIMI risk score ≥2) or at high risk of bleeding and who are already receiving ASA and clopidogrel, upstream GP IIb/IIIa inhibitors are not recommended. (Level of Evidence: B) |
” |
See Also
Sources
- The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction[5]
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina / Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline) [4]
References
- ↑ Kastrati A, Mehilli J, Neumann FJ; et al. (2006). "Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial". JAMA. 295 (13): 1531–8. doi:10.1001/jama.295.13.joc60034. PMID 16533938. Unknown parameter
|month=ignored (help) - ↑ Giugliano RP, White JA, Bode C; et al. (2009). "Early versus delayed, provisional eptifibatide in acute coronary syndromes". N. Engl. J. Med. 360 (21): 2176–90. doi:10.1056/NEJMoa0901316. PMID 19332455. Unknown parameter
|month=ignored (help) - ↑ Cannon CP, McCabe CH, Wilcox RG; et al. (2000). "Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial". Circulation. 102 (2): 149–56. PMID 10889124. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP (2011). "2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31820f2f3e. PMID 21444889. Retrieved 2011-03-30. Unknown parameter
|month=ignored (help) - ↑ Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter
|month=ignored (help)